3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
113
Neoplasms
8
HER2-positive Breast Cancer
8
Neoplasm Metastasis
6
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Inflammatory Breast Neoplasms
4
Hematologic Neoplasms
3
Brain Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Locally Advanced Breast Cancer
2
HER2-positive Metastatic Breast Cancer
2
HER2-positive Early Breast Cancer
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Ductal, Breast
2
Breast Neoplasms, Male
2
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Solid Tumor
1
Skin Neoplasms
1
Sarcoma
1
Interventions
Blood Specimen Collection
25
Reverse Transcriptase Polymerase Chain Reaction
7
Flow Cytometry
7
Liquid Biopsy
4
cabazitaxel
3
Surgical Procedures, Operative
3
Propofol
3
Carboplatin
3
Bevacizumab
3
Trastuzumab
2
Spinal Puncture
2
Sevoflurane
2
Positron Emission Tomography Computed Tomography
2
Pirinitramide
2
Neoadjuvant Therapy
2
Morphine
2
Laparoscopy
2
Hematologic Tests
2
Folfox protocol
2
Epirubicin
2
Drug Therapy
2
Docetaxel
2
Cyclophosphamide
2
Cisplatin
2
Cetuximab
2
Capecitabine
2
Aspirin
2
Anesthesia, General
2
ribociclib
1
pertuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplastic Cells, Circulating
×
pertuzumab
×
Clear all
NCT04993014
2021-08-06
HER2Cell
AC Camargo Cancer Center
Phase 2
Recruiting
80 enrolled